Health care giant Biogen has announced plans to acquire gene therapy company Nightstar Therapeutics.
In a statement on Monday, Biogen said that it will acquire Nightstar for $25.50 per share pending customary closing conditions. The deal, which values Nightstar at $800 million after expenses, is an all-cash acquisition that will give Biogen a foothold in both gene therapy and eye care.
Nightstar has several gene therapy assets, but Biogen called one, the “NSR-REP1,” the most important of the bunch. NSR-REP1 is a possible treatment for a rare disorder of the retina called choroideremia that leads to blindness. There are currently no approved treatments for choroideremia, but Nightstar’s NSR-REP1 has shown improvement in the treatment of choroideremia in trials and could be the first approved treatment for the disorder at some point in the future.
Biogen CEO Michel Vounatsos said in a statement that “ophthalmology is an emerging growth area” for the company, which made Nightstar and its NSR-REP1 an attractive acquisition target. Nightstar also has candidates in its pipeline to address a variety of other eye disorders.
Biogen said that the deal still requires Nightstar shareholder approval, but doesn’t require the approval of Biogen’s shareholders. It’s using its current cash on hand to acquire Nightstar. The companies hope to close the deal by the middle of 2019.
By Don Reisinger
Source: Fortune
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
